Company type | Aktieselskab |
---|---|
Industry | Pharmaceuticals, health care [1] |
Founded | 1958 [1] |
Headquarters | Copenhagen, Denmark [1] |
Website | http://www.xellia.com |
Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen [1] specialized in the production of anti-biotics, including Vancomycin [2] and Bacitracin. [3]
The company's US base of operations is in Buffalo Grove, Illinois, [4] [5] with additional facilities in Ohio, and North Carolina. [6] [7] In 2018, Xellia's sales in the United States accounted for 60% of its total revenue. [5]
The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.
Active drug substances manufactured are: [8]
ATC | Substance | Structural formula | Formulation for sale | Production started |
---|---|---|---|---|
D06AX05 (
WHO) (
FK) J01XX10 ( WHO) ( FK) R02AB04 ( WHO) ( FK) QA07AA93 ( WHO) ( FK) |
Bacitracin ( MT) [9] [10] | Bacitracin | 1952 | |
D06AX05 (
WHO) (
FK) J01XX10 ( WHO) ( FK) R02AB04 ( WHO) ( FK) QA07AA93 ( WHO) ( FK) |
Bacitracin ( MT) [9] [10] | Bacitracin zinc | 1958 | |
Colistimethate natrium (CMS) | ||||
A07AA10 (
WHO) (
FK) J01XB01 ( WHO) ( FK) QJ51XB01 ( WHO) ( FK) |
Colistin | Colistin sulfate | 1969 | |
J01X X09 | Daptomycin ( MT) [9] [11] | Daptomycin | ||
R02AB30 ( WHO) ( FK) | Gramicidin | |||
A07AA05 (
WHO) (
FK) J01XB02 ( WHO) ( FK) S01AA18 ( WHO) ( FK) S02AA11 ( WHO) ( FK) S03AA03 ( WHO) ( FK) QJ51XB02 ( WHO) ( FK) |
Polymyxin B ( MT) [9] [12] | Polymyxin B-sulfate | 1968 | |
J01GB01 (
WHO) (
FK) S01AA12 ( WHO) ( FK) |
Tobramycin ( MT) [9] [13] | Tobramycin sulfate | 2005 | |
D06AX08 (
WHO) (
FK) R02AB02 ( WHO) ( FK) S01AA05 ( WHO) ( FK) |
Tyrothricin | Tyrothricin | ||
A07AA09 (
WHO) (
FK) J01XA01 ( WHO) ( FK) |
Vancomycin ( MT) [9] [14] | Vancomycin hydrochloride | 2003 | |
A01AB04 (
WHO) (
FK) A07AA07 ( WHO) ( FK) G01AA03 ( WHO) ( FK) J02AA01 ( WHO) ( FK) |
Amfotericin B ( MT) [9] [15] | Amfotericin B | 1985 | |
J02AX04 ( WHO) ( FK) | Caspofungin ( MT) [9] [16] | Caspofungin acetate | ||
D07AC17 (
WHO) (
FK) R01AD08 ( WHO) ( FK) R01AD58 ( WHO) ( FK) R03BA05 ( WHO) ( FK) |
Fluticasone ( MT) [9] [17] | Fluticasone propionate | ||
D07AC13 (
WHO) (
FK) R01AD09 ( WHO) ( FK) R03BA07 ( WHO) ( FK) |
Mometasone ( MT) [9] [18] | Mometasone furoate |
Previously the company also produced:
Ingredient | Produced |
---|---|
Neomycin | 1952-? |
Tetracycline | 1961-? |
In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market. [4] [19] [20] [21] [22]
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war. [23]
Company type | Aktieselskab |
---|---|
Industry | Pharmaceuticals, health care [1] |
Founded | 1958 [1] |
Headquarters | Copenhagen, Denmark [1] |
Website | http://www.xellia.com |
Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen [1] specialized in the production of anti-biotics, including Vancomycin [2] and Bacitracin. [3]
The company's US base of operations is in Buffalo Grove, Illinois, [4] [5] with additional facilities in Ohio, and North Carolina. [6] [7] In 2018, Xellia's sales in the United States accounted for 60% of its total revenue. [5]
The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.
Active drug substances manufactured are: [8]
ATC | Substance | Structural formula | Formulation for sale | Production started |
---|---|---|---|---|
D06AX05 (
WHO) (
FK) J01XX10 ( WHO) ( FK) R02AB04 ( WHO) ( FK) QA07AA93 ( WHO) ( FK) |
Bacitracin ( MT) [9] [10] | Bacitracin | 1952 | |
D06AX05 (
WHO) (
FK) J01XX10 ( WHO) ( FK) R02AB04 ( WHO) ( FK) QA07AA93 ( WHO) ( FK) |
Bacitracin ( MT) [9] [10] | Bacitracin zinc | 1958 | |
Colistimethate natrium (CMS) | ||||
A07AA10 (
WHO) (
FK) J01XB01 ( WHO) ( FK) QJ51XB01 ( WHO) ( FK) |
Colistin | Colistin sulfate | 1969 | |
J01X X09 | Daptomycin ( MT) [9] [11] | Daptomycin | ||
R02AB30 ( WHO) ( FK) | Gramicidin | |||
A07AA05 (
WHO) (
FK) J01XB02 ( WHO) ( FK) S01AA18 ( WHO) ( FK) S02AA11 ( WHO) ( FK) S03AA03 ( WHO) ( FK) QJ51XB02 ( WHO) ( FK) |
Polymyxin B ( MT) [9] [12] | Polymyxin B-sulfate | 1968 | |
J01GB01 (
WHO) (
FK) S01AA12 ( WHO) ( FK) |
Tobramycin ( MT) [9] [13] | Tobramycin sulfate | 2005 | |
D06AX08 (
WHO) (
FK) R02AB02 ( WHO) ( FK) S01AA05 ( WHO) ( FK) |
Tyrothricin | Tyrothricin | ||
A07AA09 (
WHO) (
FK) J01XA01 ( WHO) ( FK) |
Vancomycin ( MT) [9] [14] | Vancomycin hydrochloride | 2003 | |
A01AB04 (
WHO) (
FK) A07AA07 ( WHO) ( FK) G01AA03 ( WHO) ( FK) J02AA01 ( WHO) ( FK) |
Amfotericin B ( MT) [9] [15] | Amfotericin B | 1985 | |
J02AX04 ( WHO) ( FK) | Caspofungin ( MT) [9] [16] | Caspofungin acetate | ||
D07AC17 (
WHO) (
FK) R01AD08 ( WHO) ( FK) R01AD58 ( WHO) ( FK) R03BA05 ( WHO) ( FK) |
Fluticasone ( MT) [9] [17] | Fluticasone propionate | ||
D07AC13 (
WHO) (
FK) R01AD09 ( WHO) ( FK) R03BA07 ( WHO) ( FK) |
Mometasone ( MT) [9] [18] | Mometasone furoate |
Previously the company also produced:
Ingredient | Produced |
---|---|
Neomycin | 1952-? |
Tetracycline | 1961-? |
In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market. [4] [19] [20] [21] [22]
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war. [23]